Toward classification of BRCA1 missense variants using a biophysical approach.
Carriers of germ line mutations in breast cancer susceptibility gene BRCA1 have an increased risk of developing breast and ovarian cancers; missense mutations have, however, been difficult to assess for disease association. Here we have used a biophysical approach to classify these variants. We established an assay for measuring the thermodynamic stability of the BRCA1 BRCT domains and investigated the effects of 36 missense mutations. The mutations show a range of effects. Some do not change the stability, whereas others destabilize the protein by as much as 6 kcal mol(-1); one-third of the mutants could not be expressed in soluble form in Escherichia coli, and we conclude that these destabilize the protein by an even greater amount. We tested several computer algorithms for their ability to predict the mutant effects and found that by grouping them into two classes (destabilizing by less than or more than 2.2 kcal mol(-1)), the algorithms could predict the stability changes. Importantly, with the exception of the few mutants located in the binding site, none showed a significant reduction in affinity for phosphorylated substrate. These results indicate that despite very large losses in stability, the integrity of the structure is not compromised by the mutations. Thus, the majority of mutations cause loss of function by reducing the proportion of BRCA1 molecules that are in the folded state and increasing the proportion of molecules that are unfolded. Consequently, small molecule stabilization of the structure could be a generally applicable preventative therapeutic strategy for rescuing many BRCA1 mutations.
Rowling
Pamela J E
PJ
Medical Research Council (MRC) Cancer Cell Unit, Hutchison/MRC Research Centre, Hills Road, Cambridge CB2 0XZ, United Kingdom.
Cook
Rebecca
R
Itzhaki
Laura S
LS
D000465:Algorithms; D019313:BRCA1 Protein / Q000737:chemistry* / Q000235:genetics* / Q000378:metabolism; D001665:Binding Sites / Q000235:genetics; D001943:Breast Neoplasms / Q000235:genetics; D004926:Escherichia coli / Q000235:genetics; D005260:Female; D005454:Fluorescence Polarization; D018095:Germ-Line Mutation; D019791:Guanidine / Q000494:pharmacology; D006801:Humans; D008958:Models, Molecular; D016297:Mutagenesis, Site-Directed; D050505:Mutant Proteins / Q000737:chemistry / Q000145:classification / Q000378:metabolism; D020125:Mutation, Missense; D010051:Ovarian Neoplasms / Q000235:genetics; D010748:Phosphopeptides / Q000737:chemistry / Q000378:metabolism; D017510:Protein Folding / Q000187:drug effects; D055550:Protein Stability; D017434:Protein Structure, Tertiary; D011994:Recombinant Proteins / Q000737:chemistry / Q000378:metabolism; D013696:Temperature; D013816:Thermodynamics
D019313:BRCA1 Protein; D050505:Mutant Proteins; D010748:Phosphopeptides; D011994:Recombinant Proteins; D019791:Guanidine